Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study

Brucellosis is regarded as one of the world’s most severe zoonotic diseases. This study aimed to investigate the p ossibility of using recombinant Lactococcus lactis ( L. lactis ) as a live vector to produce recombinant Brucella abortus ( B. abortus ) Omp10 . The gene sequences were obtained from GenBank. The proteins’ immunogenicity was assessed using Vaxijen. After confirming the cloning of the Omp10 gene in the pNZ8148 vector by enzymatic digestion and PCR, transformation into L. lactis was done. SDS-PAGE and western blot methods evaluated omp10 protein expression. Mice received oral recombinant L. lactis vaccines. IgG antibodies against Omp10 were tested using ELISA. Real-time PCR and ELISA were used to analyze cytokine responses. Survival rate and histopathological changes were evaluated after the challenge. Omp10 was chosen for its 1.5524 antigenicity score. Enzymatic digestion and PCR identified a 381-bp gene fragment. A 10 kDa band indicated the success of L. lactis transformation. Mice administered the L. lactis -pNZ8148- Omp 10-Usp45 vaccination 14 days after priming showed significantly higher Omp10 -specific total IgG and IgG1 ( P < 0.001) than the PBS control group. The mice who received the L. lactis -pNZ8148- Omp10 -Usp45 and IRBA vaccines had significantly elevated levels of IFN-γ, TNFα, IL-4, and IL-10 in samples collected on days 14 and 28 ( P < 0.001). Inflammatory response, morphological damage, alveolar edema, and lymphocyte infiltration were reduced in the target group. A recombinant L. lactis expressing the Omp10 protein was constructed as an oral Lactococcus -based vaccine and compared to live attenuated vaccines for future brucellosis investigations.